Estrella Immunopharma Inc (ESLAW) Q1 2024 Earnings Report

Estrella Immunopharma, a preclinical-stage biotechnology company focused on T-cell therapies for hematologic cancers and solid tumors, reported QQ1 2024 results with no revenue and a substantial net loss of $3.378 million for the quarter ended September 30, 2024. R&D expenditure amounted to $2.826 million and G&A was $0.551 million, yielding total operating expenses of $3.377 million and an EBITDA of $(3.377) million. The company generated negative operating cash flow of $2.218 million in the quarter, and ended the period with cash and cash equivalents of $1.798 million, reflecting a net cash burn of approximately $2.368 million for the quarter after financing activities. The balance sheet shows liquidity constraints: current ratio 0.748 and cash ratio 0.601, with total liabilities of $2.989 million and accumulated deficit of $22.878 million. Shareholders’ equity stood at $0.746 million, and a weighted average of ~36.21 million basic shares were outstanding. Given the lack of revenue and the early-stage pipeline (EB103/EB104 in preclinical development) the company remains heavily dependent on external financing to sustain operations and advance milestones. Despite a QoQ improvement in operating and net income of about 14% in QQ1 2024 versus the prior quarter, year-over-year comparisons remain negative as the losses persist in the preclinical phase. The near-term outlook hinges on successful preclinical milestones, potential collaborations, and the availability of additional financing to extend the operating runway.